Medical devices, healthcare technology and the business of care
510(k) clearance · K260173

M-Vizion Femoral Revision System Extension

Medacta International S.A. · Decision date Sep 17, 2026

MEDTECHLEDGER EXPLANATIONK260173

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on September 17, 2026 for K260173, a Traditional 510(k) from Medacta International S.A. for the M-Vizion Femoral Revision System Extension, classified under product code LZO with secondary codes KWY and KWZ in the orthopedic specialty. SE denotes 510(k) clearance, not premarket approval. The submission describes a range extension to the M-Vizion Monoblock (K212327) and M-Vizion Femoral Revision System (K191816, K170690) and to the MectaCer Biolox Delta Heads (K112115).

The changed items are M-Vizion Monoblock Stem small sizes (diameter 10 to 11), M-Vizion Distal Stem straight small sizes (diameter 10 to 11), M-Vizion Distal Stem curved, and MectaCer Biolox Delta Head size 22.2 M. The summary states equivalence to the listed predicates across indications, design, fixation, materials, biocompatibility, usage, packaging, shelf-life and sterility, with the range of product as the stated difference, supported by design validation and fatigue testing. The summary excerpt ends mid-list of non-clinical studies, so the full test set is not established here.

The source does not state a clinical rationale for the added sizes beyond covering a wider population, and no post-market or comparative clinical outcomes are reported. The decision letter is addressed to Christopher Lussier at Medacta USA, while the 510(k) summary names Stefano Baj as contact person; the public notification lists a receipt date of January 21, 2026.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Orthopedic
Decision date
Sep 17, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K260173
Regulatory pathway
510(k) premarket notification
Product code
LZO
Decision code
SESE
Decision date
Sep 17, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, Hip, Semi-Constrained, Metal/Ceramic/Polymer, Cemented Or Non-Porous, Uncemented.

Product code
LZO
FDA device class
2

FDA decision timeline

  1. K260173 received

    Application receipt date recorded by FDA.

  2. K260173 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code LZO

Product / regulatory recordCompanyPathwayDecision dateSource
Microport Orthopedics, Inc.510(k) clearanceOct 1, 2026FDA
United Orthopedic Corporation510(k) clearanceSep 2, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medacta International S.A.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Castel San Pietro

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records